Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant in Treatment-Naïve Type 2 Diabetes (SERENADE)
NCT00257257Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2005
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Rimonabant 20 mg with Placebo (2 arms). Primary endpoint: Hemoglobin A1c at 6 months. Started Mar 2005; status: completed.
02
Drugs
rimonabant
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00257257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257257.